Supratentorial Astrocytomas and Oligodendrogliomas Treated in the MRI Era
| Autor: | Kenji Takai, Osamu Watanabe, Emiko Tsuchida, Kunio Sakai, Masato Hareyama, Jiroh Watarai, Koh-ichi Sakata, Hiroki Shirato, Shogo Yamada, Takashi Komae |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Oligoastrocytoma Oligodendroglioma Astrocytoma medicine Humans Radiology Nuclear Medicine and imaging Anaplastic Oligoastrocytoma neoplasms Survival rate Aged Retrospective Studies business.industry Supratentorial Neoplasm Supratentorial Neoplasms Radiotherapy Dosage General Medicine Middle Aged Prognosis medicine.disease Combined Modality Therapy Magnetic Resonance Imaging Chemotherapy regimen nervous system diseases Survival Rate Oncology Female Histopathology Radiology business |
| Zdroj: | Japanese Journal of Clinical Oncology. 31:240-245 |
| ISSN: | 1465-3621 |
| Popis: | BACKGROUND There is at present no consensus on the policy for the treatment of patients with low-grade gliomas (LGGs). METHODS This report is a retrospective multi-institutional study of 100 patients (ages 16-65 years) with astrocytoma (grade II), oligodendroglioma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma of the supratentorial areas which were treated with surgery and postoperative radiotherapy at five university hospitals in northern Japan between 1990 and 1997 when MRI was routinely used to determine the target volume. Most patients were irradiated with 50-60 Gy. The target volume usually covered the areas with T2 prolongation of MRI with a margin of 2 cm. RESULTS The disease-specific 5-year survival rate was 87.4% for patients with oligodendroglioma and 75.3% for patients with astrocytoma. Survival for patients with astrocytoma in the MRI era appears to be improved compared with historical controls in the literature. Patients with astrocytoma aged 40 years and under had a significantly better disease-specific survival rate than those over 40 years (P < 0.05) and patients with oligodendroglioma and oligoastrocytoma showed a similar tendency. Patients with astrocytoma who had over 50% of their tumor removed had a significantly better survival rate than those who had less than 50% removed (P < 0.05). Chemotherapy appeared to improve the disease-specific survival rate of patients with oligodendroglioma but not that of patients with astrocytoma. CONCLUSION Oligodendroglioma has a more protracted course of disease progression than astrocytoma. This particular feature and the sensitivity of LGGs to chemotherapy as well as their relevant prognostic factors, such as age, histopathology and amount of tumor removal, should be taken into account before any decision on treatment methods for LGGs is made. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|